YL211

· MediLink Therapeutics (Suzhou) Co., Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for YL211, covering 2026-01-02 to 2026-01-02. Get the full timeline:

Most recent: Clinical Trial Update: A Phase I Study to Evaluate the Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors [Phase 1]

See pricing